|
In a conference call with reporters, he declined to answer questions about whether Roche might reconsider its failed hostile bid of about $6.5 billion to acquire U.S. diagnostics firm Illumina Inc. Roche had announced in January an offer to buy the California-based company's shares, then raised that offer after Illumina's board rejected the bid. It let the last offer expire on April 20. The Swiss drugmaker confirmed its outlook for sales growth would be in the low to middle single-digit range at constant exchange rates this year.
[Associated
Press;
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor